PT-886 is under clinical development by Phanes Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PT-886’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-886 is under development for the treatment of metastatic gastric adenocarcinoma, pancreatic ductal adenocarcinoma and GEJ adenocarcinoma. The drug candidate is a bi-specific monoclonal antibody. It acts by targeting claudin 18.2 and CD47.
Phanes Therapeutics overview
Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for metabolic complications and various types of cancer. Our extensive experience and deep scientific know-how strongly position us to discover and advance robust therapeutic molecules. Through scientific innovation, we deliver better treatment options for patients. Our mission is to relentlessly seek scientific and technological solutions to improve the lives of patients globally.
For a complete picture of PT-886’s drug-specific PTSR and LoA scores, buy the report here.